AI Echo for Cardiac Amyloidosis
May 16, 2023
Transthyretin (ATTR) amyloidosis is emerging as an under recognized form of heart failure especially in the elderly. The aim of the study was to assess the ability of Us2.ai to assess prognosis, in this patient population, at the University College London National Amyloidosis Centre, the largest center worldwide for cardiac amylodosis.
“With Us2.ai software, in a little more than 24 hours, we analyzed all echos of more than 1,200 patients with ATTR Amyloidosis, completely automated, with no human interaction.”
